McKo Pharmaceuticals-B (02335.HK): The Phase II clinical trial of MT1002 for anticoagulation in hemodialysis patients has completed the enrollment of the first patient.

China Fortune Financial APP News, MacKay Medicine-B (02335.HK) announced that the group's independently developed investigational drug MT1002 for anticoagulation in hemodialysis patients has successfully completed the first patient enrollment in Phase II clinical trial (MT1002-II-C05), marking the official entry into the substantive execution stage of the clinical trial.